151 related articles for article (PubMed ID: 15908969)
1. Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis.
Shimada K; Yokozawa T; Atsuta Y; Kohno A; Maruyama F; Yano K; Taji H; Kitaori K; Goto S; Iida H; Morishima Y; Kodera Y; Naoe T; Morishita Y
Bone Marrow Transplant; 2005 Jul; 36(2):115-21. PubMed ID: 15908969
[TBL] [Abstract][Full Text] [Related]
2. Secondary solid tumors after allogeneic hematopoietic SCT in Japan.
Yokota A; Ozawa S; Masanori T; Akiyama H; Ohshima K; Kanda Y; Takahashi S; Mori T; Nakaseko C; Onoda M; Kishi K; Doki N; Aotsuka N; Kanamori H; Maruta A; Sakamaki H; Okamoto S;
Bone Marrow Transplant; 2012 Jan; 47(1):95-100. PubMed ID: 21358690
[TBL] [Abstract][Full Text] [Related]
3. Second solid cancers after allogeneic hematopoietic stem cell transplantation.
Gallagher G; Forrest DL
Cancer; 2007 Jan; 109(1):84-92. PubMed ID: 17131350
[TBL] [Abstract][Full Text] [Related]
4. Oral malignancies following HSCT: graft versus host disease and other risk factors.
Demarosi F; Lodi G; Carrassi A; Soligo D; Sardella A
Oral Oncol; 2005 Oct; 41(9):865-77. PubMed ID: 16084755
[TBL] [Abstract][Full Text] [Related]
5. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.
Cohen A; Rovelli A; Merlo DF; van Lint MT; Lanino E; Bresters D; Ceppi M; Bocchini V; Tichelli A; Socié G
J Clin Oncol; 2007 Jun; 25(17):2449-54. PubMed ID: 17557958
[TBL] [Abstract][Full Text] [Related]
6. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.
Chen MH; Chang PM; Li WY; Hsiao LT; Hong YC; Liu CY; Gau JP; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Bone Marrow Transplant; 2011 Apr; 46(4):567-72. PubMed ID: 20622906
[TBL] [Abstract][Full Text] [Related]
7. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.
Atsuta Y; Suzuki R; Yamashita T; Fukuda T; Miyamura K; Taniguchi S; Iida H; Uchida T; Ikegame K; Takahashi S; Kato K; Kawa K; Nagamura-Inoue T; Morishima Y; Sakamaki H; Kodera Y;
Ann Oncol; 2014 Feb; 25(2):435-41. PubMed ID: 24399081
[TBL] [Abstract][Full Text] [Related]
8. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients.
Sanz J; Arriaga F; Montesinos P; Ortí G; Lorenzo I; Cantero S; Puig N; Moscardó F; de la Rubia J; Sanz G; Sanz MA
Bone Marrow Transplant; 2007 May; 39(9):555-61. PubMed ID: 17351645
[TBL] [Abstract][Full Text] [Related]
10. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
[TBL] [Abstract][Full Text] [Related]
11. Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation.
Masserot C; Peffault de Latour R; Rocha V; Leblanc T; Rigolet A; Pascal F; Janin A; Soulier J; Gluckman E; Socié G
Cancer; 2008 Dec; 113(12):3315-22. PubMed ID: 18831513
[TBL] [Abstract][Full Text] [Related]
12. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
14. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
[TBL] [Abstract][Full Text] [Related]
16. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Reddy V; Winer AG; Eksioglu E; Meier-Kriesche HU; Schold JD; Wingard JR
Biol Blood Marrow Transplant; 2005 Dec; 11(12):1014-21. PubMed ID: 16338624
[TBL] [Abstract][Full Text] [Related]
18. Hemorrhagic cystitis following hematopoietic stem cell transplantation: incidence, risk factors and association with CMV reactivation and graft-versus-host disease.
Xu LP; Zhang HY; Huang XJ; Liu KY; Liu DH; Han W; Chen H; Chen YH; Gao ZY; Zhang YC; Lu DP
Chin Med J (Engl); 2007 Oct; 120(19):1666-71. PubMed ID: 17935666
[TBL] [Abstract][Full Text] [Related]
19. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
